Acute Coronary Syndrome (ACS) represents a spectrum of conditions associated with sudden, reduced blood flow to the heart. Ongoing advancements in ACS management have led to significant improvements in patient outcomes. This article outlines the latest advancements and best practices in ACS management.
Recent years have seen remarkable advancements in ACS management, largely focused on reducing myocardial injury and improving patient survival. These include the advent of high-sensitivity cardiac troponin assays, which have improved the accuracy of ACS diagnosis. Additionally, the development of novel antiplatelet therapies such as ticagrelor and prasugrel has enhanced the effectiveness of ACS treatment.
Best practices in ACS management encompass rapid diagnosis and risk stratification, early revascularization, and comprehensive secondary prevention. Rapid diagnosis is facilitated by high-sensitivity cardiac troponin assays, while risk stratification can be achieved through tools like the GRACE risk score. Early revascularization, either through percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), remains the cornerstone of ACS treatment. Comprehensive secondary prevention includes lifestyle modifications and pharmacotherapy with antiplatelet agents, statins, beta-blockers, and ACE inhibitors.
Despite these advancements, challenges persist in ACS management. These include the management of high-risk patients, such as those with multivessel disease or diabetes, and the optimization of dual antiplatelet therapy duration. Future research should focus on addressing these challenges to further improve patient outcomes.
Advancements in ACS management have significantly improved patient outcomes, but challenges remain. Healthcare professionals should stay abreast of the latest advancements and best practices in ACS management to deliver optimal patient care. Continuous research is needed to address ongoing challenges and further enhance ACS management.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation